School of Medicine
Showing 4,591-4,600 of 4,886 Results
-
Jenli Dawn Waters, MD
Clinical Assistant Professor, Neurosurgery
BioDr. Waters is a board-certified, fellowship-trained neurosurgeon with the Neurosurgery Program at Stanford Health Care. She is also a clinical assistant professor of neurosurgery in the Department of Neurosurgery at Stanford University School of Medicine.
Dr. Waters specializes in treating a wide range of spinal conditions. These treatments include surgery to relieve numbness or pain related to pressure on the spinal cord and procedures to repair or stabilize the spinal column (spine fusion). Her areas of expertise also include diagnosis and treatment of traumatic brain injury and brain and spinal cancers.
Dr. Waters’ research experience includes helping to develop effective strategies for diagnosing
and treating patients with different neurological cancers, including glioblastomas. As a subspecialty medical expert for spine and neurosurgery, she successfully advocated for insurance coverage of state-of-the-art, minimally invasive approaches to treating epilepsy and brain tumors.
Dr. Waters has published her work in peer-reviewed journals, including the Journal of Neurosurgery and the Journal of Neuro-Oncology. She has also authored and co-authored chapters in numerous books describing neurosurgical techniques and the diagnosis and treatment of various neurological conditions, including brain and spinal cord tumors.
Dr. Waters is a member of the Congress of Neurological Surgeons. -
Kathleen Watson
Instructor, Psychiatry and Behavioral Sciences
BioKathleen Watson, Ph.D., currently serves as an instructor at Stanford University School of Medicine, specializing in Epidemiology and Clinical Research. She co-founded Microclinic International in 2007, where she served as Chief Operating Officer until 2012, focusing on socially-based health interventions for underserved communities.
Dr. Watson's research encompasses various aspects of mental health and metabolism. She investigates the connection between insulin resistance and depression, using computational psychiatry to uncover insights into the interplay of metabolic factors in mental well-being. Additionally, her exploration of cognitive aging examines how metabolic alterations might impact cognitive decline and related disorders. Furthermore, her research in proteomics aims to identify potential biomarkers for severe major depressive disorder. Dr. Watson has recently become a part of the Stanford Autism Center for Excellence Data Core, where she works under the guidance of Dr. Booil Jo. -
Brian Wayda
Member (Postdoc), Cardiovascular Institute
Current Research and Scholarly InterestsHeart transplant policy and outcomes, cost-effectiveness, mathematical modeling
-
Robert Waymouth
Robert Eckles Swain Professor of Chemistry and Professor, by courtesy, of Chemical Engineering
BioRobert Eckles Swain Professor in Chemistry Robert Waymouth investigates new catalytic strategies to create useful new molecules, including bioactive polymers, synthetic fuels, and sustainable plastics. In one such breakthrough, Professor Waymouth and Professor Wender developed a new class of gene delivery agents.
Born in 1960 in Warner Robins, Georgia, Robert Waymouth studied chemistry and mathematics at Washington and Lee University in Lexington, Virginia (B.S. and B.A., respectively, both summa cum laude, 1982). He developed an interest in synthetic and mechanistic organometallic chemistry during his doctoral studies in chemistry at the California Institute of Technology under Professor R.H. Grubbs (Ph.D., 1987). His postdoctoral research with Professor Piero Pino at the Institut fur Polymere, ETH Zurich, Switzerland, focused on catalytic hydrogenation with chiral metallocene catalysts. He joined the Stanford University faculty as assistant professor in 1988, becoming full professor in 1997 and in 2000 the Robert Eckles Swain Professor of Chemistry.
Today, the Waymouth Group applies mechanistic principles to develop new concepts in catalysis, with particular focus on the development of organometallic and organic catalysts for the synthesis of complex macromolecular architectures. In organometallic catalysis, the group devised a highly selective alcohol oxidation catalyst that selectively oxidizes unprotected polyols and carbohydrates to alpha-hyroxyketones. In collaboration with Dr. James Hedrick of IBM, we have developed a platform of highly active organic catalysts and continuous flow reactors that provide access to polymer architectures that are difficult to access by conventional approaches.
The Waymouth group has devised selective organocatalytic strategies for the synthesis of functional degradable polymers and oligomers that function as "molecular transporters" to deliver genes, drugs and probes into cells and live animals. These advances led to the joint discovery with the Wender group of a general, safe, and remarkably effective concept for RNA delivery based on a new class of synthetic cationic materials, Charge-Altering Releasable Transporters (CARTs). This technology has been shown to be effective for mRNA based cancer vaccines.
